Simcere goes private for $490M, frees itself from public reporting
SHANGHAI – Simcere Pharmaceutical Group has completed a management buyout first announced in March and subsequent delisting from the New York Stock Exchange (NYSE:SCR). Going private will protect the company from revealing information publicly during a sensitive time as Chinese biopharmas have been rocked by bribery scandals for the past six months.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST